News

NIH Awards Ceres Nanosciences $8.2M for Wastewater-Based COVID-19 Surveillance

Ceres Nanosciences announced it has been awarded an $8.2 million contract from the National Institutes of Health’s Rapid Acceleration of Diagnostics Initiative. The funding will support the development and implementation of wastewater-based surveillance systems for COVID-19.

Manassas, Virginia-based Ceres plans to develop surveillance systems using its Nanotrap particle technology at a network of sites, with an emphasis on underserved and vulnerable populations.

In a statement, Ceres noted that wastewater surveillance can be used to monitor trends in SARS-CoV-2 infection at a population level, but that “widespread implementation has been stymied by the lack of a sensitive, rapid, high-throughput viral concentration method.”

The firm’s Nanotrap Magnetic Virus Particles can capture and concentrate viruses directly from raw sewage prior to RNA extraction, according to Ceres, and this workflow can be adapted for small- and large-scale surveillance systems.

As part of the new funding, Ceres will work with researchers at Emory University to develop and implement a wastewater-based COVID-19 surveillance system in the metro-Atlanta area “with a focus on use cases for underserved and vulnerable populations,” such as correctional facilities, low-income neighborhoods, and long-term care facilities, the firm said.

Christine Moe, a wastewater infectious disease researcher at Emory, said that the collaboration between Ceres and the university will generate “robust evidence” to support the US Center for Disease Control and Prevention’s objective of developing a national wastewater surveillance system that “meets the information needs of city, county, and state decision makers to effectively respond to the COVID-19 pandemic across multiple use cases in underserved community settings.”

In parallel to this collaboration, Ceres will also be identifying and launching a network of “centers of excellence” for high-throughput wastewater-based COVID-19 surveillance.

Ben Lepene, Ceres’s chief technology officer, noted that researchers from the University of California, San Diego recently described a Nanotrap particle high-throughput method for wastewater surveillance that can process more than 100 samples in a day “with an ability to detect one asymptomatic infected individual in a building with 415 residents.” The firm expects to identify additional sites in the US to implement similar approaches.

Last year, Ceres was awarded $6.6 million from RADx to increase the manufacturing capacity of its Nanotrap Magnetic Virus Particles. The Nanotrap technology has also been also utilized for SARS-CoV-2 and Lyme disease diagnostics, as well as in liquid biopsy applications.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and